At 4 February 2019 representatives of HARMONY Patient Cluster together with HARMONY experts in research and datascience discussed the prospective outlook of Big Data in hematology for patients. In an interactive program attendees discussed the difference Big Data can make in blood cancer research and what it can mean for patients. In addition topics that will be discussed in the interactive set up are involvement of patient communities both in HARMONY projects and in related activities, as well as information needs.
The HARMONY Patient Cluster present were:
HARMONY Partner Leukanet is representing the Patient Cluster within the Alliance.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
